HUP0302160A2 - GABA agonisták és szorbitol dehidrogenáz inhibitorok kombinációját tartalmazó gyógyszerkészítmények - Google Patents

GABA agonisták és szorbitol dehidrogenáz inhibitorok kombinációját tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0302160A2
HUP0302160A2 HU0302160A HUP0302160A HUP0302160A2 HU P0302160 A2 HUP0302160 A2 HU P0302160A2 HU 0302160 A HU0302160 A HU 0302160A HU P0302160 A HUP0302160 A HU P0302160A HU P0302160 A2 HUP0302160 A2 HU P0302160A2
Authority
HU
Hungary
Prior art keywords
prodrug
sorbitol dehydrogenase
combination
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0302160A
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Products Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc., filed Critical Pfizer Products Inc.,
Publication of HUP0302160A2 publication Critical patent/HUP0302160A2/hu
Publication of HUP0302160A3 publication Critical patent/HUP0302160A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A jelen találmány tárgyát képezik a g-amino-butirsav (GABA), annakelőgyógyszere vagy az említett GABA-agonista vagy annak előgyógyszeregyógyszerészetileg elfogadható sója és szorbitot dehidrogenázinhibitor (SDI) vegyület, annak előgyógyszere vagy az említett SDI-vegyület és előgyógyszere gyógyszerészetileg elfogadható sója általalkotott gyógyszerkészítmények, a kombinációkat tartalmazó kitek,valamint ezeknek a kombinációknak a felhasználási eljárásai olyanemlősök, ideértve az embert is, kezelésére, amelyek olyancukorbetegséggel együttjáró szövődményektől szenvednek többek között,mint a cukorbetegséggel együttjáró idegbántalom, a vesebetegség, aszívizom betegség, a szemideghártya bántalom, a kis erek bántalma, anagy erek betegsége, a szürkehályog vagy a lábszárfekélyek. Ó
HU0302160A 2000-11-30 2001-11-19 Pharmaceutical compositions containing the combination of gaba agonists and sorbitol dehydrogenase inhibitors HUP0302160A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25006900P 2000-11-30 2000-11-30
PCT/IB2001/002213 WO2002043762A2 (en) 2000-11-30 2001-11-19 Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Publications (2)

Publication Number Publication Date
HUP0302160A2 true HUP0302160A2 (hu) 2003-11-28
HUP0302160A3 HUP0302160A3 (en) 2005-05-30

Family

ID=22946187

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302160A HUP0302160A3 (en) 2000-11-30 2001-11-19 Pharmaceutical compositions containing the combination of gaba agonists and sorbitol dehydrogenase inhibitors

Country Status (38)

Country Link
US (1) US6544998B2 (hu)
EP (1) EP1337271B1 (hu)
JP (1) JP2004514699A (hu)
KR (1) KR20030059290A (hu)
CN (1) CN1477975A (hu)
AP (1) AP2001002360A0 (hu)
AR (1) AR031431A1 (hu)
AT (1) ATE281181T1 (hu)
AU (1) AU2002215159A1 (hu)
BG (1) BG107774A (hu)
BR (1) BR0115783A (hu)
CA (1) CA2430298A1 (hu)
CR (1) CR6964A (hu)
CZ (1) CZ20031399A3 (hu)
DE (1) DE60106968T2 (hu)
DO (1) DOP2001000289A (hu)
EA (1) EA200300432A1 (hu)
EC (1) ECSP034624A (hu)
EE (1) EE200300248A (hu)
ES (1) ES2230378T3 (hu)
HR (1) HRP20030420A2 (hu)
HU (1) HUP0302160A3 (hu)
IL (1) IL155704A0 (hu)
IS (1) IS6786A (hu)
MA (1) MA26964A1 (hu)
MX (1) MXPA03004870A (hu)
NO (1) NO20032441L (hu)
OA (1) OA12534A (hu)
PA (1) PA8534101A1 (hu)
PE (1) PE20020597A1 (hu)
PL (1) PL365927A1 (hu)
PT (1) PT1337271E (hu)
SK (1) SK6192003A3 (hu)
SV (1) SV2003000751A (hu)
TN (1) TNSN01169A1 (hu)
UY (1) UY27042A1 (hu)
WO (1) WO2002043762A2 (hu)
ZA (1) ZA200303381B (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
OA12604A (en) * 2001-05-25 2006-06-08 Warner Lambert Co Liquid pharmaceutical composition.
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
KR20070020022A (ko) * 2004-04-02 2007-02-16 임팩스 라보라토리즈, 인코포레이티드 Ｇａｂａ 수용체 효능제에 대한 제어 방출 제형
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
MX2007010076A (es) 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
EP2142529B1 (en) 2007-04-27 2013-12-25 Purdue Pharma LP Trpv1 antagonists and uses thereof
JP5452494B2 (ja) * 2007-10-09 2014-03-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンフォチアミンと１または２種以上の医薬活性剤とを含む神経因性の疼痛状態の処置のための医薬組成物
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
WO2012050907A2 (en) * 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
RU2621708C2 (ru) 2011-06-22 2017-06-07 ПУРДЬЮ ФАРМА Эл. Пи. Антагонисты trpv1, включающие дигидроксигруппу в качестве заместителя, и их применение
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN114206349A (zh) 2019-04-17 2022-03-18 指南针探路者有限公司 治疗神经认知障碍、慢性疼痛及减轻炎症的方法
SG11202111822QA (en) * 2019-05-07 2021-11-29 Univ Miami Treatment and detection of inherited neuropathies and associated disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
GR68380B (hu) 1979-06-01 1981-12-28 Wellcome Found
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
AU3503300A (en) * 1999-02-24 2000-09-14 Regents Of The University Of California, The Gaba receptors mediate inhibition of t cell responses
WO2000059510A1 (en) * 1999-04-01 2000-10-12 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
ATE264311T1 (de) * 1999-04-01 2004-04-15 Pfizer Prod Inc Verbindungen zur behandlung und vorsorge bei diabetes

Also Published As

Publication number Publication date
UY27042A1 (es) 2002-07-31
US6544998B2 (en) 2003-04-08
DOP2001000289A (es) 2003-02-15
CA2430298A1 (en) 2002-06-06
EP1337271A2 (en) 2003-08-27
AU2002215159A1 (en) 2002-06-11
BR0115783A (pt) 2003-09-16
CN1477975A (zh) 2004-02-25
EA200300432A1 (ru) 2003-10-30
ZA200303381B (en) 2004-04-30
CZ20031399A3 (cs) 2004-04-14
WO2002043762A3 (en) 2003-03-13
ECSP034624A (es) 2003-07-25
HUP0302160A3 (en) 2005-05-30
KR20030059290A (ko) 2003-07-07
AR031431A1 (es) 2003-09-24
EE200300248A (et) 2003-10-15
SK6192003A3 (en) 2004-07-07
MA26964A1 (fr) 2004-12-20
ES2230378T3 (es) 2005-05-01
PA8534101A1 (es) 2002-10-31
DE60106968T2 (de) 2005-11-03
PL365927A1 (en) 2005-01-10
WO2002043762A2 (en) 2002-06-06
HRP20030420A2 (en) 2004-08-31
SV2003000751A (es) 2003-01-13
DE60106968D1 (de) 2004-12-09
IL155704A0 (en) 2003-11-23
NO20032441L (no) 2003-07-03
PE20020597A1 (es) 2002-07-08
EP1337271B1 (en) 2004-11-03
PT1337271E (pt) 2005-01-31
US20020091128A1 (en) 2002-07-11
NO20032441D0 (no) 2003-05-28
AP2001002360A0 (en) 2001-12-31
OA12534A (en) 2006-06-05
MXPA03004870A (es) 2003-08-19
JP2004514699A (ja) 2004-05-20
TNSN01169A1 (fr) 2005-11-10
BG107774A (en) 2004-01-30
CR6964A (es) 2004-02-02
ATE281181T1 (de) 2004-11-15
IS6786A (is) 2003-04-14

Similar Documents

Publication Publication Date Title
HUP0302160A2 (hu) GABA agonisták és szorbitol dehidrogenáz inhibitorok kombinációját tartalmazó gyógyszerkészítmények
ATE469674T1 (de) 5-aminolävulinsäure-derivate zur behandlung von akne
CN110198708B (zh) 用于组合疗法的药物组合物
MA26946A1 (fr) Derives de pyrazole nouveaux et leur utilisation comme inhibiteurs de proteine-kinases.
BRPI0416628A (pt) uso de compostos orgánicos
CY1108823T1 (el) Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3
HUP0301749A2 (hu) Acilfenil-karbamid-származékok, eljárás az elżállításukra és gyógyszerkénti alkalmazásuk
IS2734B (is) Pýrasólafleiður og notkun þar á, ásamt lyfjasamsetningum
NO20054958L (no) Substitulerte aminokarboksylsyrer
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
HUP0001286A2 (hu) Karbazol-ecetsavat tartalmazó, kutyák fájdalmának és gyulladásának kezelésére alkalmas gyógyszerkészítmény
EA200500376A1 (ru) Триазольные производные в качестве ингибиторов трансформирующего фактора роста (tgf)
WO2007054514A3 (en) Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure
BRPI0608654C1 (pt) uso de 5-amino-1-b-d-(5-benzilamino-5-desóxi-1-b-d-ribofuranosil)imidazol-4-carboxamida, 5-amino-1-(5-amino-5-desóxi-b-d-ribofuranosil)imidazol-4-n-[(4-clorofenil)metil]carboxamida ou um sal dos mesmos
NO20051011L (no) Kirale oksazol-arylpropionsyrederivater og anvendelse derav som PPAR agonister
ATE305777T1 (de) Mittel zur verhinderung der chronischen abstossreaktion infolge einer organtransplantation
EA200801308A1 (ru) Комбинации, включающие ингибитор cdk и антитело фактора роста, или антимитотик
WO2003048122A3 (en) Inhibitors of cytosolic phospholipase a2
EA200700406A1 (ru) Производные хиназолина , применяемые для лечения поражений периферических артерий и в качестве ингибиторов фосфодиэстеразы
Benyahia et al. Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the precontractile agents
JP2002105067A (ja) ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物
ATE384714T1 (de) Pyrazolderivate
Shen et al. Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension
NO20080860L (no) Substituert propanamidderivat og farmasoytisk preparat som inneholder dette
EP1802297A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES CAUSED BY YERSINIA SPP INFECTION